Literature DB >> 7684652

Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody.

Y Dohi1, S Sunada, M Aoki, A Moriguchi, M Okabayashi, M Miyata, H Matsuda.   

Abstract

The possibility of in vivo removal of metastatic tumour cells from lymph nodes by local intradermal administration of an anti-CD3 monoclonal antibody (mAb) was examined. Murine tumour cells in the lymph nodes were completely eradicated by intradermal injections of the mAb. This treatment was effective for removal of Lewis lung cancer cells from lymph nodes, but not for removal of subcutaneous tumours of this cell line. This treatment induced in vivo cytotoxicity in the regional lymph nodes against the syngeneic tumour cells. The following in vitro studies suggested that the cytotoxicity was probably mediated mainly by CD4+ T cells, with slight participation of CD8+ T cells. Normal lymph node and spleen cells showed cytotoxicity after in vitro incubation with the mAb for 2 days. Cell sorting with a fluorescein-activated cell sorter showed that CD4+ T cells developed during the incubation to lyse syngeneic tumor cells directly by themselves, macrophages not being involved in this tumour cell lysis. The lytic activity was detected in the cellular fractions, but not in the culture supernatants of these T cells. Furthermore, it was completely blocked by specific antiserum for tumour necrosis factor-alpha (TNF alpha). An immunoprecipitation study revealed that these T cells expressed TNF alpha molecules of 26 kDa, but not of 17 kDa, suggesting that tumour cell lysis was caused by membrane-integrated integrated TNF alpha molecules. These results strongly suggest that local administration of anti-CD3 antibody is a very effective and appropriate procedure for eradication of metastatic tumour cells from regional lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684652     DOI: 10.1007/bf01742251

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Tumor necrosis factor: receptors on hematopoietic cells.

Authors:  R Munker; J DiPersio; H P Koeffler
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

2.  Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones.

Authors:  S Shaw; G E Luce; R Quinones; R E Gress; T A Springer; M E Sanders
Journal:  Nature       Date:  1986 Sep 18-24       Impact factor: 49.962

3.  In vivo administration of anti-CD3 prevents malignant progressor tumor growth.

Authors:  J D Ellenhorn; R Hirsch; H Schreiber; J A Bluestone
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

4.  Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Authors:  O Leo; M Foo; D H Sachs; L E Samelson; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

5.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.

Authors:  M Kriegler; C Perez; K DeFay; I Albert; S D Lu
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

6.  Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cells.

Authors:  A Kawasaki; Y Shinkai; Y Kuwana; A Furuya; Y Iigo; N Hanai; S Itoh; H Yagita; K Okumura
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

7.  Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.

Authors:  T Nishimura; Y Nakamura; Y Takeuchi; Y Tokuda; M Iwasawa; A Kawasaki; K Okumura; S Habu
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

8.  Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.

Authors:  E Lotzová; C A Savary; R B Herberman; K B McCredie; M J Keating; E J Freireich
Journal:  Nat Immun Cell Growth Regul       Date:  1987

9.  Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells.

Authors:  M Tsujimoto; Y K Yip; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro.

Authors:  B Robaye; R Mosselmans; W Fiers; J E Dumont; P Galand
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

View more
  4 in total

1.  Lymph Node Reaction to Cancer. (Immunohistochemical and Ultrastructural Study).

Authors:  Dmitry E Tsyplakov; Semion V Petrov; Roman N Kulagin
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1.

Authors:  M Yamada; K Yanaba; M Hasegawa; Y Matsushita; M Horikawa; K Komura; T Matsushita; A Kawasuji; T Fujita; K Takehara; D A Steeber; T F Tedder; S Sato
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma.

Authors:  Vladimir Bobek; Katarina Kolostova; Daniela Pinterov; Michael Boubelik; Ping Jiang; Meng Yang; Robert M Hoffman
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction.

Authors:  D W Hoskin; T Reynolds; J Blay
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.